Pharmacogenomic profiling of 14,490 Koreans with long-read characterization of CYP2D6 and HLA
This study establishes the largest population-scale pharmacogenomic reference for Koreans by analyzing 14,490 individuals and utilizing long-read sequencing to resolve complex loci like CYP2D6 and HLA, thereby highlighting significant ancestry-specific genetic variations essential for precision medicine in East Asian populations.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Every person carries a unique set of instructions in their DNA that determines how their body handles the world around them, including the medicines they take. While a standard dose of a drug works perfectly for one person, it might be ineffective or even dangerous for another. This difference often comes down to specific genes that act like switches, turning the body's chemical processing engines up, down, or off entirely. For decades, scientists have mapped these genetic switches to help doctors prescribe the right medicine for the right patient, a field known as pharmacogenomics. However, most of the maps created so far were drawn using data from people of European ancestry. This left a significant gap in understanding for the rest of the world, particularly for people in East Asia, whose genetic makeup can differ in ways that change how they respond to treatment. Without accurate maps for these populations, the promise of personalized medicine remains out of reach for millions.
To fill this gap, researchers from the Korea National Institute of Health and Theragen conducted the largest study of its kind to date, focusing specifically on the Korean population. They analyzed the genetic data of 14,490 individuals, a massive group that allowed them to see patterns invisible in smaller studies. The team used a specialized genetic chip, a tool that reads millions of specific spots in the DNA, and combined it with a reference panel built from thousands of whole-genome sequences from Koreans. This approach allowed them to create a detailed portrait of how common drug-metabolizing genes vary within this population. They found that the genetic landscape for drug response in Koreans is distinct from that of Europeans and even differs in important ways from other East Asian groups. For instance, nearly all individuals in the study carried genetic variations that make them more sensitive to warfarin, a common blood thinner, suggesting that standard dosing guidelines used elsewhere might not be safe or effective for them. Similarly, almost half of the participants had genetic profiles that would slow down the processing of clopidogrel, a heart medication, potentially requiring a different dosage to work correctly.
While the large-scale study provided a broad view, the researchers knew that some parts of the human genome are too complex for standard tools to read accurately. Two of these difficult regions are the CYP2D6 gene, which helps process about 20 percent of common drugs, and the HLA system, which controls the immune system's reaction to foreign substances. These areas are like tangled knots of DNA, where copies of genes are duplicated, deleted, or mixed together in ways that confuse standard short-read sequencing methods. To untangle these knots, the team performed a deeper, more precise analysis on 132 individuals using long-read sequencing technology. This method reads much longer stretches of DNA at once, allowing the scientists to see the full structure of these complex genes rather than just guessing at the pieces.
The results of this deep dive were revealing. In the case of CYP2D6, the researchers discovered that the gene often exists in expanded forms in Koreans, with some people carrying multiple extra copies of a specific variant that reduces the gene's function. Current medical guidelines, which rely on counting gene copies to decide on drug dosages, struggle to interpret these complex expansions, often leaving doctors without a clear answer. The long-read sequencing showed that these expanded structures are common in Koreans but are rarely seen in European populations, meaning that existing guidelines might fail to protect Korean patients from under- or overdosing. The study also uncovered a hidden layer of diversity in the immune system's HLA genes. While the researchers confirmed that Koreans share many immune gene variants with other East Asians, they also found numerous rare and previously unknown variants that do not appear in global databases. Some of these variants are linked to severe allergic reactions to certain medications, and their absence from current records means doctors might not be able to predict these risks for Korean patients using standard tests.
This work establishes a new foundation for medicine in Korea and across East Asia. By combining a massive population survey with high-resolution genetic mapping, the researchers have shown that relying on data from other parts of the world is not enough to ensure safe and effective treatment for everyone. They have provided a reference that doctors can use to understand the specific genetic risks and needs of Korean patients, moving the field closer to a future where a prescription is tailored not just to the disease, but to the unique genetic makeup of the person being treated. The study confirms that while the tools of precision medicine are powerful, they must be built on local data to truly work for everyone.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.